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Abstract
Background: Histologic characteristics have proven to be very useful for classifying different types of tumors of the
pancreas. As a result, the major tumor types in the pancreas have long been classified based on their microscopic
appearance.
Main body: Recent advances in whole exome sequencing, gene expression profiling, and knowledge of
tumorigenic pathways have deepened our understanding of the underlying biology of pancreatic neoplasia. These
advances have not only confirmed the traditional histologic classification system, but also opened new doors to
early diagnosis and targeted treatment.
Conclusion: This review discusses the histopathology, genetic and epigenetic alterations and potential treatment
targets of the five major malignant pancreatic tumors - pancreatic ductal adenocarcinoma, pancreatic
neuroendocrine tumor, solid-pseudopapillary neoplasm, acinar cell carcinoma and pancreatoblastoma.
Keywords: Pancreas, Pancreatic cancer, Acinar cell carcinoma, Pancreatic neuroendocrine tumor,
Solid-pseudopapillary neoplasm, Genetics, Histology, Methylation, microRNA, Sequencing
Background
Malignant neoplasms of the pancreas are currently classi-
fied based on the cellular direction of differentiation
(ductal, acinar or neuroendocrine) of the neoplastic cells,
combined with the macroscopic appearance (solid or cystic)
of the tumors. Pancreatic ductal adenocarcinoma comprises
about 90 % of all malignant pancreatic neoplasms. Of all
other malignant pancreatic neoplasms (pancreatic neuroen-
docrine tumors, solid-pseudopapillary neoplasm, acinar cell
carcinoma and pancreatoblastoma), neuroendocrine tu-
mors are the most common, comprising approximately 5 %
of malignant pancreatic tumors (Table 1).
Recent genetic and epigenetic characterization of these
histologically distinct pancreatic tumors has increased
our understanding of common genetic signatures, and
has also identified tumor specific genetic alterations
(Table 2). In addition to serving as diagnostic tools,
some genetic alterations can be exploited as targets for
therapy, opening avenues for new treatments. In this re-
view, histology, genetics and epigenetics of malignant
pancreatic tumors and potential targets for treatment
are discussed.
Pancreatic ductal adenocarcinoma
Infiltrating ductal adenocarcinoma, also known as pancre-
atic ductal adenocarcinoma (PDAC), accounts for 90 % of
all malignant pancreatic neoplasms and occurs at a mean
age of 66 years [1]. PDAC has a very poor prognosis with
an overall 5-year survival of only 7 % [2]. At diagnosis, the
majority of patients are inoperable due to locally advanced
or metastatic disease. The median survival for patients with
metastatic disease is less than a year [3]. Moreover, by the
year 2030 pancreatic cancer is predicted to become the
second leading cause of cancer-related death in the U.S. [4].
In view of the increasing incidence and the virtually
unchanged poor prognosis of PDAC both new therapies for
established pancreatic cancer as well as methods for pre-
vention and early detection are desperately needed.
Gross and microscopic findings
PDACs are characteristically firm, ill-defined white-yellow
masses (Fig. 1a). The pancreatic parenchyma upstream
from PDACs is usually atrophic and the main pancreatic
duct can be dilated. Microscopically, PDAC is composed
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Table 1 Differential diagnosis of malignant pancreatic neoplasms. Overview of pancreatic neoplasms with their relative prevalence, direction of differentiation, macroscopic and




















90 % 66 (11) Male (3:2) Ductal Solid • Glandular and ductal structures
• Abundant desmoplastic stroma
• Eosinophilic to clear cytoplasm
and enlarged pleomorphic
nuclei
• Perineural, lymphatic and blood
vessel invasion
Aberrant TP53 expression, SMAD4 loss,








• Nested or trabecular growth
pattern
• Granular amphophilic to
eosinophilic cytoplasm
• “Salt and pepper” chromatin
Expression of synaptophysin and chromogranin, peptide
hormones (e.g. insulin and glucagon), aberrant nuclear




1–2 % 29 (14) Female (9:1) Uncertain Solid and
cystic
• Poorly cohesive uniform cells
• Extensive degenerative
changes.
• Eosinophilic or clear vacuolated
cytoplasm Round to oval nuclei,
often grooved or indented.
• Eosinophilic globules and
foamy macrophages
Abnormal nuclear labeling for β-catenin, expression of CD10,
paranuclear dot-like CD99 labeling or lymphoid enhancer-
binding factor 1 (LEF1). Loss of membranous E-cadherin
Acinar cell
Carcinoma








• Enlarged uniform nuclei with
prominent nucleoli
• Finely granular eosinophilic
cytoplasm.
• Small acinar units or sheets
BCL10, expression of pancreatic exocrine enzymes:
trypsin, chymotrypsin, lipase




Slightly male Acinar Solid, cystic
in BWS a
• Similar to ACC
• Squamoid nests required for
diagnosis
• Neuroendocrine or ductal
component.
Expression of pancreatic exocrine enzymes, BCL10,



















Major genes involved Methylation MiRNA tumor expression




20–80 KRAS, CDNK2A, SMAD4, TP53,
MLL3, TGFBR2, ATM, ARID1A,
ROBO2, KDM6A
Loss of function through promotor
hypermethylation: CDNK2A, hMLH1,
Upregulation: miR-21, 23a, 31, 100,






16 MEN1, ATRX, DAXX, TSC2,
PTEN#, Rb, TP53*
Hypomethylation of LINE1 and
hypermethylation of RASSF1A promoting
the accumulation of β-catenin






3 CTNNB1 u MiRNAs possibly upregulating the




131 SMAD4, JAK1, BRAF, RB1, TP53,




Upregulation: miR-17, 20, 21, 92–1,
103, 107
Downregulation: miR-155
Pancreatoblastoma 18 Loss of chromosome 11p,
CTNNB1
Hypermethylation of RASSF1A u
u unknown. # MEN1, ATRX, DAXX, TSC2 and PTEN mutations are found in well-differentiated PanNET but not in PanNEC. * Rb and TP53 mutations are present in
PanNEC, but not in well-differentiated PanNET
Fig. 1 a Macroscopic appearance of a pancreatic ductal adenocarcinoma showing a poorly demarcated firm white tumor in the pancreatic
parenchyma (T Tumor, P pancreatic parenchyma, D duodenum). b Perineural invasion of a pancreatic ductal adenocarcinoma. c Positive TP53
immunohistochemistry in pancreatic ductal adenocarcinoma indicative of TP53 gene mutation. Arrow, malignant ductal structure; arrowhead,
normal pancreatic duct. d Loss of SMAD4 immunohistochemistry in pancreatic ductal adenocarcinoma indicating mutation of the SMAD4 gene.
Arrow, malignant ductal structure; arrowhead, normal pancreatic duct
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of haphazardly arranged infiltrating glandular and ductal
structures typically surrounded by abundant desmoplastic
stroma. The cells have eosinophilic to clear cytoplasm and
usually enlarged pleomorphic nuclei. Poorly differentiated
ductal adenocarcinomas have more irregular and smaller
glands and significant pleomorphism. Perineural, lymph-
atic and blood vessel invasion are frequently present
(Fig. 1b). The neoplastic cells in areas of venous invasion
can be so well-differentiated that they mimic non-invasive
precursor lesions (pancreatic intraepithelial neoplasia).
Immunohistochemically, there is no definite marker to
distinguish PDAC from non-neoplastic ductal structures,
although aberrant TP53 expression or SMAD4 loss support
the diagnosis of PDAC over reactive glands (Fig. 1c and d)
[5, 6]. Several types of mucin (MUC1, MUC3, MUC4,
MUC5AC) and glycoprotein tumor antigens such as
CA19-9 can be expressed in PDAC [7–9]. The main micro-
scopic differential diagnosis consists of PDAC precursor
lesions, other malignant pancreatic tumors (Table 1),
pancreatitis and adenocarcinoma metastasis.
PDAC develops from precursor lesions that can be either
microscopic (pancreatic intraductal neoplasia, PanIN) or
macroscopic cystic precursor lesions (intraductal papillary
mucinous neoplasm, IPMN; mucinous cystic neoplasm,
MCN) (Fig. 2). IPMN and MCN are often found as inci-
dental finding on imaging. PanIN arises in microscopic
ducts; IPMN arises within the main- or branch-ducts.
MCN usually does not communicate with the ductal sys-
tem. Microscopically, all precursors show flat or papillary
mucin-producing neoplastic epithelium, with varying de-
grees of dysplasia and directions of differentiation. Stepwise
accumulation of (epi)genetic alterations drives neoplastic
progression and eventually development of malignant inva-
sive carcinoma, analogous to the PanIN progression model
as depicted in Fig. 3 and discussed below [10, 11].
Genetic signature: familial PDAC
Approximately 10 % of pancreatic cancers appear to have
an inherited component. Overall, sporadic and familial
PDAC share the same driver mutations (KRAS, CDKN2A,
TP53 and SMAD4) [12], but some of these cases are
caused by inherited germline genetic alterations in genes
that significantly increase the risk of pancreatic cancer
(Table 3). These genes include BRCA2, BRCA1, PALB2,
p16/CDKN2A, ATM, STK11, PRSS1, and the DNA mis-
match repair genes (such as MLH1 and MSH2) [13–17].
In addition, a number of other candidate genes, such as
BUB1B, CPA1, FANCC and FANCG, have been described
[12]. These germline alterations are critical to understand
because the risk is significant and at-risk patients can be
enrolled in screening and early detection protocols for
pancreatic and extra-pancreatic tumors [18]. In addition,
some patients with specific genetic alterations can be pri-
oritized for specific therapies. For example, some tumors
Fig. 2 a Low-grade pancreatic intraepithelial neoplasia (PanIN)
showing micro-papillary epithelium with mild to moderate
cytological atypia. b Intraductal papillary mucinous neoplasm (IPMN),
gastric-foveolar type with low-grade dysplasia. c Mucinous cystic
neoplasm (MCN) showing gastric-foveolar type epithelium with low-
grade dysplasia, surrounded by ovarian-type stroma
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characterized by microsatellite instability due to a DNA
mismatch repair gene defect are exquisitely responsive to
immunotherapies, and some tumors with BRCA or PALB2
gene mutation are sensitive to poly ADP ribose polymer-
ase (PARP)-inhibitors [19–21].
In addition to these low prevalence but high pene-
trance genes, there are a number of more common
lower penetrance genes that increase the risk of pancre-
atic cancer only slightly. A number of these, including
ABO blood group type, have been identified in genome
wide association studies (GWAS) [22–24].
Genetic signature: sporadic PDAC
The somatic alterations present in PDAC are now well
characterized thanks to several large whole-exome and
whole-genome sequencing studies [21, 25–27]. On
average PDACs have 50–80 exomic non-silent mutations
[21, 25–27]. In addition, extensive larger structural varia-
tions including intra-chromosomal rearrangements, dele-
tions and amplifications are common in PDAC [21, 28].
Point mutation of the oncogene KRAS is seen in al-
most all early pancreatic cancer precursor lesions and
in PDACs. Subsequent mutations that drive neoplastic
progression in PanIN lesions are usually in the tumor
suppressor genes CDKN2A, TP53 and SMAD4 (Fig. 3)
[21, 25, 26]. Further accumulation of genetic and epi-
genetic alterations drives neoplastic progression in
these precursor lesions, eventually leading to an inva-
sive pancreatic adenocarcinoma [10]. Less commonly
mutated genes in PDAC include MLL3, TGFBR2,
ATM, ARID1A, ROBO2 and KDM6A [21, 25–27]. Of
note, mutations in chromatin-regulating genes (MLL,
MLL2, MLL3 and ARID1A) have been associated with
improved survival, and loss of SMAD4 with poorer
survival [29, 30]. Many mutations found by whole
exome sequencing are reported in a very low percent-
age of tumors, and therefor categorized as passengers
in tumorigenesis. Of note the recently proposed “mini
driver” model hypothesizes that several passengers
might have relatively weak tumor-promoting effects
but together might substitute for a major-driver [31].
More research is needed to address the exact role of most
of these less prevalent mutations in tumorigenesis.
Importantly - despite the diversity of genes targeted - the
genetic alterations in PDAC appear to selectively target
core signaling pathways, including Wnt/Notch signaling,
Table 3 Overview of germline genetic alterations with well-
defined pancreatic cancer risk and genes that have been associated
with familial PDAC
Gene (syndrome) RR (Cumulative
lifetime risk (%)
by age 70)
STK11/LKB1 (Peutz-Jeghers syndrome) 132 (36)
PRSS1/SPINK1 (hereditary pancreatitis) 50–80 (40)
CDKN2A (FAMMM) 13–47 (17)
BRCA1/BRCA2 (HBOC) 3.5–10 (3–8)
MLH1, MSH2, MSH6, PMS2 (Lynch syndrome) 8.6 (<5)
CFTR (cystic fibrosis) 5 (<5)
FDR with PC 2–3 (2)
FDRs with PC 6 (8–12)
Possible role in FPC:
ATM, TET2, DNMT3A, POLN, POLQ, ASXL1, PALB2, FANCG,
BUB1B, ESCO2, FANCC, FANCM, MSH4, RAD54L
Unknown
RR relative risk, FDR first degree relative, FAMMM familial atypical multiple
mole melanoma, HBOC hereditary breast and ovarian cancer syndrome, FAP
familial adenomatous polyposis, PC pancreatic cancer, FPC familial pancreatic
cancer. Adapted from Ghiorzo et al. and Roberts et al. [12, 151]
Fig. 3 Pancreatic cancer develops from the well-defined precursor lesions pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm
and mucinous cystic neoplasm. The PanIN progression model shown here shows that accumulation of genetic and epigenetic alterations drives neoplastic
progression in these precursor lesions from low-grade dysplasia (PanIN 1 and PanIN 2) to high-grade dysplasia (PanIN 3) to eventually an invasive
pancreatic adenocarcinoma
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TGF-β signaling, and DNA damage control [26]. Despite
the genetic heterogeneity of PDAC, targeting one or more
of these pathways may be more effective than targeting a
specific genetic alteration. For example, Waddell et al. re-
cently correlated deleterious mutations in BRCA1 and
BRCA2 with unstable genetic signatures (>200 structural
variations). In their study, 4 out of 5 patients with defective
DNA damage control responded to treatment with a plat-
inum containing regimen. Also PARP inhibitors have been
reported to be effective in BRCA mutated tumors [21].
These findings illustrate how knowledge of rare mutations
in known pathways can be used to guide treatment. A
number of clinical trials targeting specific pathways and
mutations are being conducted on patients with PDAC and
other human cancers. Potential targets for therapeutic
intervention are seen in over a third of PDACs (up to 97 %
when trials related to KRAS and TP53 are included) [29].
Future personalized treatment might thus drastically
change outcome of this disease.
Studies of the clonal evolution of genetic changes in
pancreatic cancer and metastases by Yachida et al. sug-
gest that it takes almost 12 years from the initiating mu-
tation in the pancreas until development of an invasive
PDAC [32]. This suggests a wide window of opportunity
for the early detection of pancreatic cancer. The genetic
alterations present in pancreatic cancer and its non-
invasive precursors can be shed into the blood and into
the pancreatic duct system. This suggests the possibility
of gene-based early detection tests. Indeed, mutant
KRAS shed from invasive pancreatic cancer can be
detected in the plasma, and mutations present in non-
invasive cystic precursor lesions, such as IPMNs and
MCNs can be detected in cyst fluid aspirated at the time
of endoscopic ultrasound (EUS), as well as in secretin
stimulated pancreatic juice collected from the duode-
num [33, 34].
Epigenetic alterations
A number of genes are aberrantly methylated in pancreatic
cancer [35–41]. For example, integrated methylation and
gene-expression meta-analysis have identified a number of
genes (MUC4, SERPINB5, CLDN4, SFN, TFF1, S100P,
S100A4, MMP1, MMP7, MSLN, PSCA, ID1, MST1R,
NBL1, PHLDA2, PLAT, PLAUR, IL8, SPP1, ARHGDIB,
NQO1, and ITGB4) that are significantly upregulated in
PDAC, likely caused by promoter hypomethylation [36, 42,
43]. Some of the genes targeted by changes in methylation
are clearly cancer-causing, such as the well-known tumor
suppressor gene CDNK2A and the DNA repair gene
hMLH1, which show loss of function through promoter
hypermethylation silencing [40, 44–46].
These epigenetic changes are not only functionally im-
portant, but can also be used as markers of disease and
early detection. For example, DNA methylation alterations
in the pancreatic juice are a possible approach to the diag-
nosis of pancreatic cancer [47].
MicroRNA
Post-transcriptional regulation or silencing of gene ex-
pression occurs mostly by non-coding RNAs. The most
studied non-coding RNAs are microRNAs (miRs), which
are small single stranded RNA molecules that regulate
mRNA by full or partial complementarity. Deregulated
miRs can give information on transcriptional regulation
and may serve as biomarkers for survival and early de-
tection [48–50].
Recently a large meta-analysis looked at the miR expres-
sion profiles of 538 PDACs. A statistically significant miR
meta-signature with upregulation of miR-21, 23a, 31, 100,
143, 155, and 221 and downregulation of miR-148a, 217
and 375 was found in PDAC. Furthermore, in a cohort of
70 patients, the high expression of miR-21, miR-31 and
the low expression of miR-375 in their PDACs was found
to be an independent prognostic marker for poor overall-
survival [50]. Interestingly, in stool from patients with
PDAC, significantly higher miR-21 and miR-155 and
lower miR-216 levels have been found compared to nor-
mal controls [51]. Other studies with “disease free sur-
vival” and “overall survival” as outcome measures also
found an important role for high levels of miR-21 in pre-
dicting prognosis, along with high miR-155, high miR-203,
and low miR-34a [49].
MiR-21 is thus an important candidate for diagnostic
and prognostic purposes, although it cannot be used to
differentiate between PDAC and precursor lesions such
as intraductal papillary mucinous neoplasms (IPMN) or
malignancy in other organs [52, 53]. MiR-21 has ap-
proximately 180 target messenger RNAs (mRNA) [54].
Interestingly several of these targets are tumor suppres-
sors and negative regulators of the Ras/MEK/ERK path-
way. An in vivo study with a murine non-small cell lung
carcinoma model confirmed upregulation of miR-21
with RAS activation, and downregulation of several
negative RAS regulators and tumor suppressors includ-
ing SPRY1, SPRY2, BTG2, and PDCD4 [54]. In vitro
studies have reported several other miR-21 affected
tumor suppressor mRNAs, including PTEN [55]. Dele-
tion of miR-21 has also been shown to repress tumor
formation in KRAS mutated mice and makes in vitro
cells more sensitive for chemotherapy, possibly by re-
pression of the AKT pathway through p85α inhibition
[56]. MiR-21 may thus be potentially interesting as
pharmacological target as well.
Research on miRs is booming, and many recent stud-
ies have found other and new miRs not reported in the
meta-reviews, also to be excellent prognostic markers
for PDAC [57–60]. Other forms of non-coding RNA like
long non-coding RNA (lncRNA), small nucleolar-derived
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RNA (sdRNA) and piwi-interacting RNA (piRNA) are
also differentially altered in PDAC [61].
Changes in gene expression
Several studies have tried to classify PDAC into clinically
meaningful subgroups based on gene expression profiles.
Collisson et al. clustered 3 distinct subtypes of PDAC (clas-
sical, quasimesenchymal and exocrine-like) with different
responses to treatment and different patient prognosis
[62]. Recently Moffitt et al. used blinded digital separation
of PDAC gene expression microarray data to cluster pri-
mary carcinoma, metastasis, and normal samples [63].
They found that the groups described by Collisson et al.
did not hold predictive power in their samples. Instead
they identified two tumor subtypes: “classical” which had
great overlap with the classical group of Collison et al., and
basal-like which had a worse outcome and was molecularly
similar to basal tumors in the bladder. Furthermore, as
they could digitally separate tumor and stromal expression,
they defined “normal” and “activated” stromal subtypes,
which they reported to be independent prognostic factors
[63]. Currently, there is no well-established clinically mean-
ingful subclassification of PDAC.
Differentially upregulated genes by mRNA can result
in upregulation of proteins, which - just like DNA,
miRNA and mRNA - can be used as potential diagnostic
biomarkers of malignancy in pancreatic juice and blood
[64]. Furthermore, specific mutated proteins such as
mutant Ras can be distinguished from wild-type Ras by
mass spectrometry in tissue and pancreatic juice, which
might be even more useful for early diagnosis of PDAC
and its precursors [65]. Other highly expressed proteins
including mesothelin are potentially targetable with im-
munotherapy [66]. Mutant proteins can also give rise to
aberrant epitopes on tumor MHC receptors, which then
can specifically be targeted by adoptive T-cell therapy as
elegantly demonstrated in other human cancers [67].
Stroma and the tumor microenvironment
In addition to genetic alterations, the tumor microenviron-
ment and changes in epigenetic regulation play important
roles in promoting or suppressing PDAC growth [68, 69]
and stromal expression profile has shown prognostic sig-
nificance [63]. Also, by overexpression of hyaluronic acid
and collagens, the extracellular matrix can cause a high
interstitial fluid pressure, causing compression of blood ves-
sels and therefor hindering passive transport processes of
chemotherapeutics. Targeting these stromal factors might
improve therapeutic response [70].
PDAC and its microenvironment are also marked by
distinct immune cell populations along its path of tumori-
genesis, creating an immunosuppressive environment that
shields tumor cells from detection and renders them
resistant to immune-based therapies. Regulatory T-cells
(T-reg) seem to play a role from the earliest stage of pre-
cursor disease potentially undermining anti-tumor
effector T-cell activity; high intratumor T-reg/CD4+ T-cell
ratio is a prognostic factor for worse survival. Therapeut-
ically targeting of T-regs in malignancy is currently under
investigation [70].
Pancreatic neuroendocrine tumors
Pancreatic neuroendocrine tumors (PanNET) are the sec-
ond most common malignant tumor of the pancreas [6].
PanNETs occur mostly in elderly patients, with a mean
age of 58 years [71]. Although prognosis of PanNET is
better than PDAC, it is still poor with an average overall
5 year survival of only 42 % [72]. Functional PanNETs are
well known for their classic clinical presentations includ-
ing Whipple’s triad (insulinoma) and Zollinger-Ellison
syndrome (gastrinoma), in which hypersecretion of pan-
creatic or non-pancreatic hormones have systemic effects.
When no systemic effects of hormone production are
seen, PanNETs are by definition classified as non-
functional [5].
A number of TNM classification systems with prog-
nostic value for PanNET patients have been developed
by the WHO2010 [World Health Organization], ENETs
[European Neuroendocrine Tumor Society] and AJCC
[American Joint Committee on Cancer] [73]. Although
it is at present not completely established which system
should be preferred, a recent study suggests that the
ENETs TNM classification was superior to the AJCC/
WHO2010 classification/grading System and more ac-
curate [74].
Gross and microscopic findings
PanNETs are usually soft, sometimes red or white, well-
demarcated lesions (Fig. 4a). Microscopically the neoplas-
tic cells have a nested or trabecular growth pattern. At
higher magnification, the neoplastic cells have a distinct
neuroendocrine morphology, with a granular amphophilic
to eosinophilic cytoplasm and the typical coarsely
clumped “salt and pepper” chromatin (Fig. 4b). The mi-
totic rate and percentage of Ki67 positive cells are used
for grading. The well-differentiated PanNETs can be either
grade 1 (<2 mitoses per 10 HPF; Ki-67 labeling index
<2 %) or grade 2, (2–20 mitoses per 10 HPF; Ki-67 label-
ing index 3–20 %). If mitotic count is >20 mitoses per 10
HPF or Ki-67 index is >20 %, the neoplasm is classified as
a grade 3 neuroendocrine tumor or neuroendocrine car-
cinoma (PanNEC). Histologically PanNECs can have one
of two appearances. Those with a Ki-67 <50 % can look
similar to the well-differentiated PanNETs, only they have
a high proliferation rate [75]. This group is somewhat
more aggressive than grade 2 PanNETs but not as rapidly
progressive as the PanNECs with a Ki67 >50 %. PanNECs
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with a very high proliferation rate (>50 %) can have a
small cell carcinoma or large cell carcinoma appearance
with markedly pleomorphic typical neuroendocrine cells
that are tightly packed in nests or form diffuse irregular
sheets [5]. Necrosis is often seen.
Immunohistochemical expression of neuroendocrine
markers synaptophysin and chromogranin A is seen in
the majority of PanNETs [76], and peptide hormones
(e.g. insulin and glucagon) can also confirm neuroendo-
crine differentiation. Large cell PanNECs typically ex-
press neuroendocrine markers, but small cell PanNECs
may not. Both large and small cell PanNECs are typically
negative for peptide hormones [77]. Aberrant nuclear
TP53 expression is commonly found in PanNECs but is
never seen in PanNETs [78]. The main microscopic dif-
ferential diagnosis consists of acinar cell carcinoma
(Fig. 7), pancreatoblastoma, mixed neuroendocrine tu-
mors, and dedifferentiated PDAC (Table 1).
Genetic signature: familial PanNET
The vast majority (90 %) of PanNETs occur sporadic-
ally, but some occur in the setting of associated familial
syndromes including multiple endocrine neoplasia type
1 (MEN1), von Hippel-Lindau syndrome (VHL),
neurofibromatosis type 1 (NF1), tuberous sclerosis
complex (TSC) and the recently discovered glucagon
cell adenomatosis (GCA) [5, 79]. Studies of PanNETs
occurring in patients with an underlying genetic predis-
position have provided important insight into the genes
involved in tumorigenesis of PanNETs. Tumorigenesis
in these syndromes follow a hyperplasia-neoplasia se-
quence in which hyperplastic nodules transform over
time into frank neoplasms [79–81]. It is assumed that
sporadic cases PanNETs develop through a similar
hyperplasia-neoplasia sequence. PanNECs are not asso-
ciated with germline syndromes and are believed to fol-
low a different pathway of tumorigenesis [78].
Genetic signature: sporadic PanNET
Whole exome and targeted sequencing of well differenti-
ated PanNETs (grade 1 and 2) of patients without a familial
syndrome showed an average of only 16 nonsynonymous
mutations per tumor [82]. Somatic mutations of theMEN1
gene were found in 45 % of these sporadic PanNETs [82].
Others have previously reported loss of heterozygosity at
the MEN1 locus in 20–45 % of sporadic PanNETs [83, 84].
In addition to prevalent somatic MEN1 mutations, 45 % of
sporadic PanNETs harbored somatic inactivating mutations
Fig. 4 a Macroscopic appearance of pancreatic neuroendocrine tumor showing a well-demarcated pinkish tumor surrounded by normal
pancreatic parenchyma. b Pancreatic neuroendocrine tumor, detail showing typical salt and pepper chromatin. c Loss of Menin expression
in pancreatic neuroendocrine tumor indicative of MEN1 gene inactivation. d Retained Menin expression in pancreatic neuroendocrine
tumor with a wildtype MEN1 gene
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in ATRX or DAXX, and 15 % had mutations in mTOR
pathway genes (in which TSC1/2 functions) [82]. Remark-
ably, the alternative lengthening of telomeres (ALT) pheno-
type, a mechanism of telomerase independent telomere
maintenance to overcome cell death, was found to corre-
lated perfectly with loss of ATRX and DAXX [85–87].
Moreover, many gains and losses have been reported in
sporadic PanNETs [88, 89]. VHL is deleted in 18 % of spor-
adic PanNET, and recently allelic loss of PHLDA3 - a regu-
lator of the mTOR pathway - was found in 70 % of
sporadic PanNETs [90, 91].
The genetic alterations in well-differentiated PanNETs
(grades 1 and 2) have been compared to those in Pan-
NEC (grade 3). Yachida et al. found that small and large
cell PanNECs are genetically similar, but distinct from
PanNETs [78]. In PanNECs, activating KRAS mutations
(2 of 7) and inactivating mutations in TP53 (4 of 7) and
RB1 (5 of 7) were seen. By contrast, none of these muta-
tions were found in 11 well-differentiated PanNETs. Ab-
normal expression of the TP53 (95 %) and RB1 (75 %)
proteins was also frequently seen in PanNEC, but not in
well-differentiated PanNETs. Furthermore, all PanNECs
retained expression of ATRX and DAXX, while, as noted
above, PanNETs showed loss of expression of ATRX and
DAXX in 45 % of cases (Table 4) [78].
As mentioned earlier, sporadic PanNETs likely develop
through a similar hyperplasia-neoplasia sequence as fa-
milial PanNETs. MEN1 syndrome associated PanNETs
show loss of the wild-type MEN1 allele in up to 100 %
of cases (compared to 19–44 % in sporadic PanNETs).
Loss of the wild-type MEN1 allele is also seen in microa-
denomas of MEN1 patients and is therefore an early
event [83, 92–94]. Loss of Menin can be demonstrated
by immunohistochemistry (Fig. 4c and d). In non-
syndromic patients, it is unclear which initiating events
cause microadenomas to develop, also bearing in mind
that not all sporadic PanNETs have MEN1 alterations.
ATRX and DAXX mutations with ALT activation have
been reported to correlate significantly with tumor size
and T-stage, and are thus considered a late event in
tumor progression. In total 45 % of PanNETs have alter-
ations in one of both genes [86, 87]. Although less likely,
it is not known if sporadic microadenomas have ATRX
or DAXX alterations.
In contrast to sporadic PanNETs, ATRX and DAXX
alterations were only seen in 6 % of PanNETs from
MEN1 syndrome patients (but also as late event) and
in 0 % of microadenomas suggesting a less important
role for these alterations in MEN1 syndrome tumor
progression [95].
Epigenetic alterations
Few studies investigated epigenetic alterations in PanNETs.
Hypomethylation in LINE-1 was reported in 20 % of well-
differentiated PanNETs, and strongly correlated with poor
prognosis and high stage [96]. Other studies found hyper-
methylation of the tumor suppressor gene RASSF1A in
75–80 % of PanNETs with associated decreased protein ex-
pression of RASSF1A [97, 98]. Interestingly, the RASSF1
gene has six other transcriptional variants (B-G), of which
RASSF1C was seen to be expressed 10 times higher in
PanNET than in normal tissue [98]. An in vitro study
found the balance between isoform A and C crucial for the
expression of β-catenin, where silencing RASSF1A and
expression of RASSF1C promotes the accumulation of β-
catenin by inhibiting its hTrCP mediated proteasomal
degradation [99], possibly sustaining Wnt signaling in
PanNET. RASSF1A furthermore represses miR-21 [100].
Interestingly overexpression of miR-21 which is also upreg-
ulated in PDAC, was strongly associated with both a high
Ki67 proliferation index and metastasis to the liver [101],
potentially giving the RAS pathway a role in higher grades
of PanNET [54].
MicroRNA
Studies of microRNA expression have suggested that
miR-193b is a differential marker for PanNET in tissue
and serum compared to normal [102]. MiR-103 and
miR-107 were also overexpressed and miR-155 was
downregulated in PanNET [101].
Changes in gene expression
Analyses of gene-expression patterns in PanNETs have
found that a number of genes are upregulated in PanNETs,
including oncogenes (e.g. MLLT10/AF10), cell adhesion
molecules (e.g. fibronectin) and growth factors (e.g.
IGFBP3) compared to normal islets. Growth factor IGFBP3
was upregulated significantly more in metastases compared
to primary PanNETs. In addition, downregulation of tumor
suppressor genes (NME3), cell checkpoint proteins (p21/
Cip1), and transcription factor JunD that is inhibited by
Menin, have been reported [103]. Comparison of gene
expression between sporadic PanNETs and VHL associated
Table 4 Mutations in pancreatic MEN1 syndrome associated
















6 % u u u u
G1/G2 Pancreatic
neuroendocrine tumors




u 0 % u 30 % 60 % 70 %
u unknown
Hackeng et al. Diagnostic Pathology  (2016) 11:47 Page 9 of 17
PanNETs, found that VHL associated tumors follow a spe-
cific pathway with upregulation of genes related to hypoxia
inducible factor proteins (HIF) and vascular endothelial
growth factor (VEGF), both of which regulate angiogenesis
[104].
Therapeutically, PanNETs relying on angiogenesis are
theoretically targetable by blocking specific pathway
components (e.g. VEGF inhibitors) [105–107]. Similarly,
PanNETs relying on mTOR activation should be particu-
larly susceptible to everolimus, a drug which has shown
to significantly prolong survival [108].
Solid-pseudopapillary neoplasms
Solid-pseudopapillary neoplasms (SPN) are rare tumors
accounting for 1–2 % of all malignant neoplasms of the
pancreas. These neoplasms mostly occur in female
(90 %) patients at an average age of 29 years (SD: 14).
SPNs have a low malignant potential. SPNs are usually
limited to the pancreas, but 8 % of patients present
with distant metastasis. Disease free survival after cura-
tive resection is 95 % [109].
Gross and microscopic findings
SPNs are essentially solid neoplasms that often undergo
dramatic cystic degeneration creating a gross lesion with
a mixture of solid, pseudopapillary and hemorrhagic-
necrotic areas (Fig. 5a). Microscopically, these neoplasms
are composed of poorly cohesive uniform cells clinging
ineffectively to delicate capillaries surrounded by exten-
sive degenerative changes. The cells have eosinophilic or
clear vacuolated cytoplasm, and the nuclei are round to
oval and can be often grooved or indented. Rarely the
nuclei are bizarre appearing in areas with degeneration.
Eosinophilic globules and foamy macrophages are typic-
ally present in these neoplasms (Fig. 5b). SPNs can be
distinguished from other pancreatic tumors by the ex-
pression of CD10, paranuclear dot-like CD99 labeling
and abnormal nuclear labeling for β-catenin (Fig. 5c) or
lymphoid enhancer-binding factor 1 (LEF1) [110–114].
The microscopic differential diagnosis consists of neo-
plasms with a solid and cellular appearance like pancre-
atic neuroendocrine tumor, acinar cell carcinoma and
pancreatoblastoma (Table 1).
Genetic signatures: sporadic and familial SPN
Activating mutations in CTNNB1 (β-catenin) occur in
virtually all SPNs, reflected by the nuclear accumulation
of β-catenin seen in immunohistochemistry [115, 116].
Recent whole exome sequencing of SPNs found on aver-
age of only three non-synonymous mutations per tumor,
which is extremely low compared to all of the other pan-
creatic neoplasms. The CTNNB1 gene mutations all
occur in the critical region between codons 32 and 37
preventing phosphorylation and subsequent degradation
of the β-catenin protein.
Two SPNs have been reported in patients with Familial
Adenomatous Polyposis (FAP), caused by germline APC
mutations, confirming that an APC mutation is also cap-
able of driving SPN development [117, 118]. The female
predominance of SPN is not understood, but it has been
shown that estrogenic molecules can influence prolifera-
tion in vitro [119].
Epigenetic alterations
Undegraded β-catenin in SPNs forms a complex with
LEF1, enters the nucleus and activates transcription of sev-
eral oncogenes including cyclin-D1 that is overexpressed in
70–100 % of SPNs [115, 116, 120]. Cyclin-D1 and its
cyclin-dependent kinases phosphorylate the Retinoblastoma
(Rb) protein, which drives the cell in the S-phase of the cell
cycle. P21 and P27, known to inhibit Rb phosphorylation,
were shown to be upregulated in 86 and 100 % of SPNs, re-
spectively. Interestingly, hyperphosphorylated Rb was not
detectable, which might explain the low growth-rate of
SPN compared to other β-catenin mutated tumors [121].
MicroRNA and changes in gene expression
Few studies investigated gene expression and epigenetic
alterations in SPN, and all are complicated by the fact that
the normal cell that is the counterpart of the neoplastic
cell in SPNs has not been identified. These studies are
therefore, at best, comparing apples to oranges. One study
investigated mRNA and miR expression in 14 SPNs and
found 1686 genes to be differentially expressed compared
to normal pancreatic parenchyma (which is composed
mostly of acinar cells) [122]. These differentially expressed
genes activated the Wnt pathway, Hedgehog (HH) path-
way, androgen-receptor (AR) pathway and epithelial
mesenchymal transition. Moreover, 79 miRs were differen-
tially expressed in these SPNs (49 miRs upregulated, 30
miRs downregulated). By predicting miR targets, 17 of the
30 downregulated miRs possibly upregulated mRNAs in
the Wnt/HH/AR pathways [123]. A proteomic profile did
not significantly confirm these pathways, but did find up-
regulation of several proteins involved in the Wnt pathway
[122]. Another mRNA analysis in SPN found the NOTCH
pathway to be activated in addition to the Wnt Pathway
[124]. Large chromosomal rearrangements, aberrant
methylation or other non-coding RNAs have not been in-
vestigated in SPN.
Acinar cell carcinoma
Acinar cell carcinoma (ACC) is a rare neoplasm accounting
for <1 % of malignant pancreatic tumors. Median age of
presentation is 56 years (SD: 15). Most cases occur in late
adulthood, but 6 % of cases occur between 8 and 15 years
of age. There is no clear syndrome associated with ACC,
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but ACC has been reported in patients with Peutz-Jeghers
syndrome, Lynch syndrome, Familial Adenomatous Polyp-
osis, and in a patient with a germline BRCA1 mutation
[125–128].
Although 60 % of patients with ACC have distant
metastasis at presentation (similar to PDAC), overall
5-year survival is 45 % [129]. Some ACCs release di-
gestive enzymes and other products into the blood
stream, including alpha-fetoprotein and lipase [130,
131]. About 15 % of patients with ACC present with
metastatic fat necrosis, peripheral eosinophilia and ar-
thralgias caused by elevated serum lipase [132].
Gross and microscopic findings
Compared to PDAC, ACCs are relatively soft and well-
circumscribed tumors. Microscopically, ACCs are rem-
iniscent of normal exocrine pancreatic cells with en-
larged uniform nuclei with prominent nucleoli and
finely granular eosinophilic cytoplasm. The cells can
form small acinar units or sheets without a distinctive
architecture (Fig. 6a and b) [5]. Acinar cell carcinomas
express pancreatic exocrine enzymes such as trypsin,
chymotrypsin and lipase that can be detectable by im-
munohistochemistry [132]. BCL10, normally expressed
in normal acini, is also expressed in ACC and is helpful
in the differential diagnosis between ACC and other
pancreatic neoplasms such as PanNET and PDAC
(Fig. 7a and b) [133, 134]. Also the monoclonal antibody
2P-1-2-1 can be used to show acinar differentiation
[135]. The microscopic differential diagnosis consists of
neoplasms with a solid and cellular appearance like pan-
creatic neuroendocrine tumor, solid pseudopapillary
neoplasm, pancreatoblastoma (Table 1).
Genetic signature: sporadic ACC
Whole exome sequencing of ACCs revealed that these tu-
mors, on average, harbor a large number of mutations
(131 nonsynonymous somatic mutations per tumor in one
study). Also, chromosomal instability is seen with a rela-
tive high fractional allelic loss compared to PDAC.
Chromosome 11p is lost in ~50 % of ACC, suggesting that
a locus on 11p may play an important role in ACC devel-
opment [136, 137]. Many other gains and losses have been
reported including loss of the TP53 locus on 17p (25 %),
Fig. 5 a Macroscopic appearance of a solid-pseudopapillary neoplasm
showing a well demarcated tumor with solid, pseudopapillary and
hemorrhagic-necrotic pseudocystic structures. b Microscopically, SPN is
characterized by solid areas with relatively uniform cells with eosinophilic
or clear vacuolated cytoplasm admixed with delicate capillaries and areas
with extensive degenerative changes. The cells are poorly cohesive
causing the pseudopapillary appearance. Note the eosinophilic globules
(arrow). c Nuclear β-catenin expression in SPN (T tumor) and normal
membranous labelling in adjacent normal pancreatic parenchyma
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the APC locus on 5q21 (50 %), the SMAD4 locus on 18q
(60 %) and gain of the CTNNB1 (β-catenin) locus on 3p
[137–140]. Whole exome sequencing data further revealed
that no single gene was mutated in more than 30 % of
ACCs. The genes targeted include SMAD4 (25 %); JAK1
(20 %); BRAF, RB1, TP53 (13 % each); APC, ARID1A,
GNAS, MLL3, PTEN (9 % each) and ATM, BAP1, BRCA2
PALB2,MEN1, RNF43 (4 % each) [137]. Recently, a review
combined all ACC sequencing studies and found similar
results: SMAD4 mutations in 19 % of ACC, CTNNB1/
APC in 15 %,TP53 in 12 %, and BRAF in 6 % [139].
Ten percent of ACCs appear to be microsatellite
instable and may thus be sensitive to immunotherapy
[19, 139]. In addition, a number of other potentially
actionable mutations, such as BRCA and JAK1 muta-
tions, have been found in ACCs [137]. BRAF muta-
tions are rarely seen in ACC; notably, comprehensive
genomic profiling identified rearrangements in 23 %
of ACC involving either BRAF or RAS. The most
prevalent fusion SND1-BRAF activated the MAPK
pathway and made the cells sensitive for MEK in-
hibitor trametinib, so this pathway might be useful
as therapeutic target for a subgroup of patients with
ACC [141].
Epigenetic alterations and MicroRNA
The importance of the APC/β-catenin pathway for ACC
becomes more evident when methylation is taken into
account. RASSF1 and APC were reported to be methyl-
ated in 60 and 56 % of ACCs, respectively [142]. A
different study confirmed the high percentage of ACC
with APC methylation, and also found significantly more
MLH1 methylation in ACC compared to PDAC and
PanNET [143].
MiR has only been studied in four ACCs in comparison
to PanNETs. Surprisingly, 93 % of differentially upregulated
miRs and 70 % of differentially downregulated miRs in
Fig. 7 a Positive BCL10 expression in an acinar cell carcinoma. b
Negative BCL10 expression in a pancreatic neuroendocrine tumor
Fig. 6 a Macroscopic appearance of an acinar cell carcinoma. b
Microphotograph of an acinar cell carcinoma characterized by a cells
with granular cytoplasm and round to oval uniform nuclei forming
form small acinar structures
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ACC compared to normal pancreas were also up- or down-
regulated in PanNET. No specific miR was up- or downreg-
ulated in ACC versus PanNET. Overexpression of miR-17,
miR-20, miR-21, miR-92-1, miR-103 and miR-107; and lack
of expression of miR-155 was found in ACC [101].
Pancreatoblastoma
Pancreatoblastoma (PB) is another rare tumor with aci-
nar differentiation. PBs usually present in childhood at
an average age of 5 years (SD: 2), but there is also a rare
group that presents at adult age [144, 145]. The overall
5 year survival is approximately 50 %. PB is associated
with Beckwith-Wiedemann syndrome, an (epi)genetic
overgrowth-cancer predisposition disorder characterized
by exomphalos, macroglossia, and gigantism [146]. As in
ACC, serum alpha-fetoprotein and lipase can be elevated
in PB and pancreatic panniculitis has also been reported.
Gross and microscopic findings
Tumors are very similar to ACC in their acinar differen-
tiation. The distinguishing element in PB from other tu-
mors with acinar differentiation are characteristic
squamoid nests, which can vary in size and appearance
and can even show keratinization (Fig. 8). Neuroendo-
crine or ductal components may also be encountered,
but acinar differentiation and squamoid nests are both
required for the diagnosis. PB shares the same immuno-
histochemical markers for acinar differentiation with
ACC, but can also stain positive for markers of ductal or
neuroendocrine differentiation. SMAD4 expression is
immunohistochemically lost in 20 % [147], and abnor-
mal nuclear expression of β-catenin can be seen, some-
times in the squamoid nests [5, 127]. The microscopic
differential diagnosis consists of neoplasms with a solid
and cellular appearance like pancreatic neuroendocrine
tumor, solid pseudopapillary neoplasm and acinar cell
carcinoma (Table 1). In children, other tumors like
Wilms tumor and hepatoblastoma should be considered.
Genetic signature and epigenetic alterations
Patients with Beckwith-Wiedemann syndrome (germline
loss of heterozygosity of chromosome 11p) have a signifi-
cantly higher risk of pediatric tumors, amongst others pan-
creatoblastoma which has been reported in several BWS
patients [144, 146]. Interestingly loss of 11p also occurs in
more than 80 % of sporadic PBs [147]. Likely, several genes
on 11p that are expressed according to their parental origin
(imprinting) play a role in PB tumorigenesis [148]. The
APC/β-catenin pathway also plays an important role with
40 to 60 % of sporadic PBs having mutations in CTNN1B.
In addition, a case with biallelic inactivation of APC in a
FAP patient has been reported [115, 147]. Aberrant methy-
lation of the promoter RASSF1A was seen in in 2 cases
[149, 150]. No further characterization in epigenetics has
been done.
Conclusions
The underlying alterations of pancreatic cancer demon-
strate that the traditional histopathologic classification
of these neoplasms has a solid genetic basis. The genetic
changes within each tumor type add to the pathologic
classification with the identification of new prognostic
markers and new therapeutic targets.
Even with all of the advances in our understanding of
genetics of pancreatic neoplasms, the cornerstone to a
correct diagnosis is still traditional gross and micro-
scopic examination. Especially the importance of gross
inspection is often less appreciated, and yet this can
already give important clues to a correct diagnosis. For
instance, some tumors are typically solid whereas others
are typically cystic. Also, location of a tumor in the pan-
creas (head, body of tail) and whether a tumor is well
circumscribed or ill-defined can point in a certain direc-
tion. Most diagnoses of pancreatic tumors can be made
without help of additional genetic studies although
sometimes proof of a specific genetic alteration in a
tumor can further establish a presumed diagnosis. The
best example clearly is the SPN, in which virtually all
cases have the same underlying CTNNB1 mutation and
immunohistochemistry for β-catenin is routinely used in
the diagnostic workup. Also, loss of SMAD4 immuno-
histochemistry is frequently used in daily practice to
suggest pancreatic origin of an adenocarcinoma in a dis-
tant site in a patient with a pancreatic mass.
Slowly we are heading towards an era where the combin-
ation of classical morphologic pathology and genetic
characterization will be essential to establish a more accur-
ate diagnosis. Furthermore, genetic profiling is becoming
more and more important for treatment choices; for
Fig. 8 Microphotograph of pancreatoblastoma showing
characteristic squamoid nests
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instance with the choice for a targeted therapy, such as
mTOR inhibitors in pancreatic neuroendocrine tumors or
PARP inhibitors in BRCA deficient tumors. In the near fu-
ture, stromal activation, miRNA and methylation markers
might influence our choices by better predicting tumor be-
havior and prognosis. Ideally, would use our knowledge of
genetic and epigenetic alterations to screen the blood and
pancreatic juices for genetic alteration that identify patients
with a high-risk precursor lesion or an early form of cancer.
Although our understanding of the genetics of pancreatic
cancer has immensely increased in the last decade, many
years of research are still needed to integrate all this know-
ledge and translate it into day-to-day practice.
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